Whitehawk Therapeutics reports Q3 net loss of $17.7M, cash $162.6M, IND filings on track

Whitehawk Therapeutics, Inc.

2025-Q3 EPS reported $0.04 vs consensus $0.07 ▼ miss (-41.2%)

Net loss for Q3 2025 was $17.7M vs $12.5M in Q3 2024; no revenue reported.
Cash, equivalents and short-term investments $162.6M as of Sept 30, 2025, up from $47.2M at Dec 31, 2024; runway into 2028.
IND submissions for HWK-007 and HWK-016 planned by year-end 2025; HWK-206 by mid-2026.
PTK7 confirmed as broadly expressed tumor target through analysis presented at AACR-NCI-EORTC.
Management expects initial clinical data readouts across portfolio from current cash position.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.